A neuropharmacokinetic assessment of bafetinib, a second generation dual BCR-Abl/Lyn tyrosine kinase inhibitor, in patients with recurrent high-grade gliomas

European Journal of Cancer

Volumn 49, Issue 7, 2013, Pages 1634-1640

  Portnow, Jana ^a   Badie, Behnam ^a   Markel, Susan ^a   Liu, An ^a   D'Apuzzo, Massimo ^a   Frankel, Paul ^a   Jandial, Rahul ^a   Synold, Timothy W ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Bafetinib; Brain tumour; Intracerebral microdialysis; Neuropharmacokinetics

Indexed keywords

ALANINE AMINOTRANSFERASE; BAFETINIB; BCR ABL PROTEIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BACTERIAL MENINGITIS; CANCER GRADING; CANCER SURGERY; CLINICAL ARTICLE; DIALYSATE; DRUG BRAIN LEVEL; DRUG EFFICACY; DRUG SAFETY; FEMALE; GLIOMA; HUMAN; INTRACEREBRAL MICRODIALYSIS; LIMIT OF DETECTION; MALE; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MICRODIALYSIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; SIDE EFFECT; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; TUMOR BIOPSY;

ADULT; AGED; AREA UNDER CURVE; BLOOD-BRAIN BARRIER; BRAIN; BRAIN NEOPLASMS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DIALYSIS SOLUTIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FUSION PROTEINS, BCR-ABL; GLIOMA; HUMANS; KARNOFSKY PERFORMANCE STATUS; MALE; MASS SPECTROMETRY; MENINGITIS, BACTERIAL; METABOLIC CLEARANCE RATE; MICRODIALYSIS; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRIMIDINES; SRC-FAMILY KINASES; TREATMENT OUTCOME;

EID: 84876127675     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.01.001     Document Type: Article

References (38)

1. S. Kimura, H. Naito, and H. Segawa NS-187, a potent and selective dual BCR-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia Blood 106 2005 3948 3954 (Pubitemid 41739036)
2. J. Goldman, and J. Melo Chronic myeloid leukemia-advances in biology and new approaches to treatment N Engl J Med 349 2003 1451 1464 (Pubitemid 37211061)
3. F.P. Santos, H. Kantarjian, J. Cortes, and A. Quintas-Cardama Bafetinib, a dual BCR-Abl/Lyn tyrosine kinase inhibitor for the potential treatment of leukemia Curr Opin Investig Drugs 11 2010 1450 1465
4. M.R. Stettner, W. Wang, and L.B. Nabors Lyn kinase activity is the predominant cellular SRC kinase activity in glioblastoma tumor cells Cancer Res 65 2005 5535 5543 (Pubitemid 40911153)
5. K.V. Lu, S. Zhu, and A. Cvrljevic Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients Cancer Res 69 2009 6888 6898
6. V. Velcheti, B. Peterson, D. Levitt, and O. Prakash Preclinical evaluation of bafetinib for treatment of glioblastoma multiforme J Clin Oncol 28 Suppl 2010 2082 ASCO Annual Meeting Proceedings
7. M. Holdhoff, J.G. Supko, and G.L. Gallia Intratumoral concentrations of imatinib after oral administration in patients with glioblastoma multiforme J Neurooncol 97 2010 241 245
8. S. Bihorel, G. Camenisch, M. Lemaire, and J.M. Scherrmann Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier J Neurochem 102 2007 1749 1757 (Pubitemid 47329285)
9. J.F. Leis, D.E. Stepan, and P.T. Curtin Central nervous system failure in patients with chronic myelogenous leukemia lymphoid blast crisis and Philadelphia chromosome positive acute lymphoblastic leukemia treated with imatinib (STI-571) Leuk Lymphoma 45 2004 695 698 (Pubitemid 38256028)
10. P. le Coutre, K.A. Kreuzer, and S. Pursche Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588 Cancer Chemother Pharmacol 53 2004 313 323 (Pubitemid 38392356)
11. K. Neville, R.A. Parise, and P. Thompson Plasma and cerebrospinal fluid pharmacokinetics of imatinib after administration to nonhuman primates Clin Cancer Res 10 2004 2525 2529 (Pubitemid 38445714)
12. E. Razis, P. Selviaridis, and S. Labropoulos Phase II study of a neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment Clin Cancer Res 15 2009 6258 6266
13. Y. Chen, S. Agarwal, and N.M. Shaik P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib J Pharmacol Exp Ther 330 2009 956 963
14. K. Porkka, P. Koskenvesa, and T. Lundan Dasatinib crosses the blood-brain barrier and is an efficient therapy for central nervous system Philadelphia chromosome-positive leukemia Blood 112 2008 1005 1012
15. Final Report for Study No. B-5 (English Report): Tissue concentrations of radioactivity after a single oral administration of 14C-CML-187 to male rats. Nippon Shinyaku Co., Ltd., Kyoto, Japan. 03 February, 2005.
16. + leukemia cells in the central nervous system, and cyclosporine A augments its in vivo activity Blood 109 2007 306 314
17. H. Dai, P. Marbach, M. Lemaire, M. Hayes, and W.F. Elmquist Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux J Pharmacol Exp Ther 304 2003 1085 1092 (Pubitemid 36254421)
18. A. Hamada, H. Miyano, H. Watanabe, and H. Saito Interaction of imatinib mesylate with human P-glycoprotein J Pharmacol Exp Ther 307 2003 824 828 (Pubitemid 37310701)
19. H. Kantarjian, P. le Coutre, and J. Cortes Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in Philadelphia chromosome-positive leukemias after imatinib resistance or intolerance Cancer 116 2010 2665 2672
20. D.R. Macdonald, T.L. Cascino, S.C. Schold Jr, and J.G. Cairncross Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 8 1990 1277 1280 (Pubitemid 20195640)
21. J. Portnow, B. Badie, and J. Chen The neuropharmacokinetics of temozolomide in patients with resectable brain tumors: potential implications for the current approach to chemoradiation Clin Cancer Res 15 2009 7092 7098
22. E.C. de Lange, B.A. de Boer, and D.D. Breimer Microdialysis for pharmacokinetic analysis of drug transport to the brain Adv Drug Deliv Rev 36 1999 211 227 (Pubitemid 29121973)
23. J. Blakeley, and J. Portnow Microdialysis for assessing intratumoral drug disposition in brain cancers: a tool for rational drug development Expert Opin Drug Metab Toxicol 6 2010 1477 1491
24. Bafetinib Investigator's Brochure. 5th ed. January, 2010.
25. 11C]verapamil and tariquidar at the human blood-brain barrier: a comparison with rat data Clin Pharmacol Ther 91 2012 227 233
26. Y. Uchida, S. Ohtsuki, and Y. Katsukura Quantitative targeted absolute proteomics of human blood-brain barrier transporters and receptors J Neurochem 117 2011 333 345
27. S. Syvanen, O. Lindhe, and M. Palner Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport Drug Metab Dispos 37 2009 635 643
28. J. Chu, and J.M. Gallo Application of microdialysis to characterize drug disposition in tumors Adv Deliv Rev 45 2000 243 253
29. Q. Zhou, and J.M. Gallo In vivo microdialysis for PK and PD studies of anticancer drugs AAPS J 7 2005 E659 E667
30. Y. Wang, S.L. Wong, and R.J. Sawchuk Microdialysis calibration using retrodialysis and zero-net flux: application to a study of the distribution of zidovudine to rabbit cerebrospinal fluid and thalamus Pharm Res 10 1993 1411 1419 (Pubitemid 23302655)
31. A.T. Bergenheim, M. Roslin, and U. Ungerstedt Metabolic manipulation of glioblastoma in vivo by retrograde microdialysis of l-2, 4 diaminobutyric acid (DAB) J Neuroooncol 80 2006 285 293 (Pubitemid 44782906)
32. J.O. Blakeley, J. Olson, S.A. Grossman, X. He, J. Weingart, and J.G. Supko Effect of blood brain barrier permeability in recurrent high grade gliomas on the intratumoral pharmacokinetics of methotrexate: a microdialysis study J Neurooncol 91 2009 51 58
33. E. Raymond, A.A. Brandes, and C. Dittrich Phase II study of imatinib in patients with recurrent gliomas of various histologies: a European Organisation for Research and Treatment of Cancer Brain Tumor Group Study J Clin Oncol 26 2008 4659 4665
34. P.Y. Wen, W.K. Yung, and K.R. Lamborn Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08 Clin Cancer Res 12 2006 4899 4907 (Pubitemid 44338577)
35. D.A. Reardon, M.J. Egorin, and J.A. Quinn Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme J Clin Oncol 23 2005 9359 9368
36. D.A. Reardon, G. Dresemann, and S. Taillibert Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma Br J Cancer 15 2009 1995 2004
37. A. Desjardins, J.A. Quinn, and J.J. Vredenburgh Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas J Neurooncol 83 2007 53 60 (Pubitemid 46647165)
38. G. Dresemann, M. Weller, and M.A. Rosenthal Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide J Neurooncol 96 2010 393 402